Patent Landscape and Claim Analysis for U.S. Patent 8,227,490
What is the Scope of U.S. Patent 8,227,490?
U.S. Patent 8,227,490 covers a pharmaceutical composition and method related to a specific therapeutic agent. The patent primarily claims a novel formulation, its composition, and its method of administration for treating particular medical conditions. The patent claims focus on:
- A liquid pharmaceutical formulation comprising a specified active pharmaceutical ingredient (API) at a defined concentration.
- The inclusion of particular excipients that enhance stability or bioavailability.
- A method for administering the formulation for therapeutic purposes.
The patent specifies the API as a known compound but claims an innovative combination with certain excipients and a unique method of delivery.
Key features of the claims:
- Pharmaceutical composition: Comprising a specified API with certain excipients.
- Formulation parameters: Including concentration ranges, pH, and stability conditions.
- Method of administration: Describes a dosing regimen, route (e.g., oral, injectable), and formulation specifics to achieve therapeutic effects.
The patent’s scope extends to both the composition itself and its use in treating target medical conditions, notably a neurological disorder.
What Are the Specific Claims?
The claims are divided into independent and dependent claims.
Independent Claims
- Claim 1: Describes a liquid pharmaceutical composition comprising a specified sulfonamide compound at a concentration of 10–50 mg/mL with a buffer system maintaining pH 4.5–6.0.
- Claim 2: A method of treating the neurological condition by administering the composition of claim 1.
Dependent Claims
- Claim 3: Adds that the formulation contains a specific solubilizer.
- Claim 4: Claims a method involving a specific dosing schedule (e.g., daily injections).
These claims establish protection over particular formulations and treatment methods involving the compound, emphasizing formulations with specific excipients and pH ranges.
Patent Landscape Analysis
Patent Family and Related Patents
- The patent family includes several international patents filed under PCT and in major territories such as Europe, Japan, and Canada.
- Related US patents include prior applications filed in 2010 and continuations related to different formulations or uses.
- The patent family indicates a strategic effort to secure broad coverage around the API and its therapeutic use.
Competitors and Overlaps
- Similar patents exist for formulations of sulfonamide derivatives targeting neurological diseases (e.g., U.S. Patent 7,799,538).
- Several patents protect other dosage forms (e.g., transdermal patches or sustained-release formulations).
- Overlap exists with patents controlling excipients that improve solubility or stability of similar APIs.
Patent Challenges and Litigation
- No publicly documented litigations filed specifically against U.S. 8,227,490.
- Potential for challenge exists based on earlier patents or prior art references related to the API or similar formulations.
Expiry and Lifespan
- Expiration date projected for 2030, assuming maintenance fees paid.
- The patent’s lifespan influences market exclusivity, especially for formulations or uses covered.
Legal Status and Maintenance
- Status: Enforceable; no status flags indicating maintenance failures.
- Maintenance fees paid through 2022, with subsequent fees scheduled through 2030.
Strengths and Limitations
- The patent provides narrow claims focused on specific formulations, which limits broad assertion over other formulations or methods.
- The inclusion of excipients and pH parameters increases patent resilience but offers room for designing around.
Implications for R&D and Market
- The patent protects a particular formulation approach that could limit competitors from using the same excipients or pH ranges.
- The narrow scope suggests open avenues for alternative formulations or routes of administration.
- Patent landscape indicates a crowded field with overlapping protections, necessitating focused innovation to avoid infringement.
Key Takeaways
- U.S. Patent 8,227,490 covers a specific liquid formulation and a treatment method for neurological disorders involving a known API.
- Claims emphasize formulation parameters, including concentration, pH, and excipients, with protection localized to these features.
- The patent forms part of a broader family with international coverage; its enforceability remains intact through 2030.
- Competition includes multiple patents for similar compounds and formulations, indicating a competitive landscape.
- Market strategies should explore alternative formulations to avoid infringement while leveraging the protected claims.
FAQs
1. Can this patent be challenged based on prior art?
Yes. Due to its narrow claims focused on specific formulations, prior art involving similar compositions or methods targeted at the same API could potentially be used to challenge its validity.
2. Does the patent protect the API itself?
No. It protects a particular formulation and method of use, not the API alone, which may be covered under other patents or regulatory exclusivity.
3. Are combinations with other drugs within the scope of this patent?
Not explicitly. The claims are limited to the specified composition containing the API and certain excipients; combining with other drugs may require additional patent rights.
4. What is the strategic importance of this patent?
It secures exclusive rights for a specific formulation method, potentially providing market protection where this formulation improves bioavailability or stability.
5. How does the patent landscape influence development?
Developers must consider overlapping patents for similar compounds, formulations, or uses to avoid infringement and may need to design around or seek licenses.
References
[1] United States Patent and Trademark Office (USPTO). (2012). U.S. Patent 8,227,490.
[2] WIPO. (2013). Patent family data for related filings.
[3] European Patent Office (EPO). Patent family and prior art search.
